AMD

Nutanix Unveils Programming for the 2021 Global .NEXT Digital Experience, the Leading Hybrid Multicloud Conference

Retrieved on: 
Tuesday, August 31, 2021
Data Management, Security, Technology, Software, Networks, Internet, Xchange, Ecosystem, AMD, Fujitsu, Organization, Social media, Research, Solution, EMEA, Publication, The X Factor Digital Experience, Public relations

The Partner Xchange will feature a special keynote featuring Nutanix leaders, industry experts and thought leaders plus the annual partner awards followed by dedicated breakout sessions.

Key Points: 
  • The Partner Xchange will feature a special keynote featuring Nutanix leaders, industry experts and thought leaders plus the annual partner awards followed by dedicated breakout sessions.
  • Organizations around the world use Nutanix software to leverage a single platform to manage any app at any location for their hybrid multicloud environments.
  • Learn more at www.nutanix.com or follow us on social media @nutanix
    2021 Nutanix, Inc. All rights reserved.
  • Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries.

Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, August 31, 2021
Retina, AMD, Glaucoma, PALO, Therapy, ABC, Science, Severe cognitive impairment, Research, Nasdaq, KOD, CA, Patient, Conference, Morgan Stanley, Pharmaceutical industry

PALO ALTO, Calif., Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, at 8:45 a.m. Pacific Time (11:45 a.m. Eastern Time).

Key Points: 
  • PALO ALTO, Calif., Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, at 8:45 a.m. Pacific Time (11:45 a.m. Eastern Time).
  • Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases.
  • Our ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine.
  • Kodiak, Kodiak Sciences, ABC, ABC Platform and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

AMD EPYC™ Processors Picked by Argonne National Laboratory to Prepare for Exascale Future

Retrieved on: 
Monday, August 30, 2021
Aurora, AMD, Hewlett Packard Enterprise, Engineering, GLOBE, HPE, Argonne National Laboratory, DOE, Research, Astronomy, AI, U.S. Department of Defense Strategy for Operating in Cyberspace, CPU, NASDAQ, Carbon, HPC, Gen, EPYC, Video game console

SANTA CLARA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) announced that the U.S. Department of Energy’s (DOE) Argonne National Laboratory (Argonne) has chosen AMD EPYC™ processors to power a new supercomputer, called Polaris, which will prepare researchers for the forthcoming exascale supercomputer at Argonne called Aurora. Polaris is built by Hewlett Packard Enterprise (HPE), will use 2nd Gen EPYC processors and then upgrade to 3rd Gen AMD EPYC processors, and will allow scientists and developers to test and optimize software codes and applications to tackle a range of AI, engineering, and scientific projects.

Key Points: 
  • The new Polaris supercomputer will optimize AI, engineering, and scientific projects for forthcoming exascale supercomputer at Argonne National Laboratory
    SANTA CLARA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) announced that the U.S. Department of Energys (DOE) Argonne National Laboratory (Argonne) has chosen AMD EPYC processors to power a new supercomputer, called Polaris, which will prepare researchers for the forthcoming exascale supercomputer at Argonne called Aurora.
  • Polaris is built by Hewlett Packard Enterprise (HPE), will use 2 nd Gen EPYC processors and then upgrade to 3 rd Gen AMD EPYC processors , and will allow scientists and developers to test and optimize software codes and applications to tackle a range of AI, engineering, and scientific projects.
  • We are extremely proud to support Argonne National Laboratory and their critical research into areas including low carbon technologies, medical research, astronomy, solar power and more as we draw closer to the exascale era.
  • Polaris will use the AMD EPYC 7532 and EPYC 7543 processors, and NVIDIA A100 Tensor Core GPUs, to deliver approximately 44 petaflops of peak double precision performance, which is 4x faster than Argonnes current supercomputers.

Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

Retrieved on: 
Monday, August 30, 2021
Industry, Company, AMD, Retina, Population, Fast track (FDA), Drug development, Fast Track, U.S. Securities and Exchange Commission, GLOBE, SEC, U.S.–Canada Team Tournament (go), Board of directors, Neurotransmission, Research, Nasdaq, Private Securities Litigation Reform Act, Food, DME, Investment, Board, Overalls, Prospectus, Diabetic retinopathy, ASX, Safety, Patient, CEO, VEGF, FDA, Annual report, COVID-19, Patent, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Management, Cryptocurrency

MELBOURNE, Australia, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today reported financial results for the year ended June 30, 2021 and provided an overview of recent progress and accomplishments.

Key Points: 
  • In March 2021, Opthea announced that the first patient had been treated in its Phase 3 pivotal program for OPT-302 for wet AMD.
  • In March 2021, Opthea announced that it received an initial Pediatric Study Plan (iPSP) waiver from the U.S. Food and Drug Administration (FDA) for OPT-302.
  • In August 2021, Opthea announced the expansion of the Phase 3 ShORe and COAST wet AMD trials of OPT-302 into Canada.
  • A copy of Optheas financial results and Annual Report for the financial year ending June 30, 2021 is available on the Companys website www.opthea.com/annual-reports/ .

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

Retrieved on: 
Monday, August 30, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AMD, Population, Ageing, Retina, Twitter, Drug Quality and Security Act, Smoking, U.S. Securities and Exchange Commission, IVT, Night vision, SEC, PK, Social media, Geographic atrophy, Biomarker, Factor, Severe cognitive impairment, Nasdaq, Western world, Food, Disease, Therapy, Clinical trial, Regulation of tobacco by the U.S. Food and Drug Administration, CNV, Forward-looking statement, CFH, Investor, Securities Act of 1933, File, Reading, Safety, Risk, Intravitreal injection, Summit, Patient, Visual acuity, LinkedIn, CTS, Eye, Oxygen toxicity, A-DNA, FDA, Boat, Annual report, COVID-19, Anetoderma, Medical device, Risk management, Pharmaceutical industry, Medical imaging, Dietary supplement, Vaccine, the Phase 2a ReGAtta Study, GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics, THE PHASE 2A REGATTA STUDY, GEM103, DRY AGE-RELATED MACULAR DEGENERATION (AMD), GEMINI THERAPEUTICS

We were pleased to have the opportunity to present at the Clinical Trials at the Summit to further discuss our initial data released from our Phase 2a ReGAtta study of GEM103 in patients with GA secondary to dry AMD, said Dr. Barone.

Key Points: 
  • We were pleased to have the opportunity to present at the Clinical Trials at the Summit to further discuss our initial data released from our Phase 2a ReGAtta study of GEM103 in patients with GA secondary to dry AMD, said Dr. Barone.
  • The current ongoing Phase 2a study is open-label, uncontrolled, and was not designed to detect statistically significant treatment effect.
  • Additional 26 patients were enrolled in a second cohort and received three monthly doses of 500g of GEM103 intravitreally.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

D&H Leaders Win Accolades From Prestigious Channel and Retail Media

Retrieved on: 
Thursday, August 26, 2021
Cloud, Recreation, 104th United States Congress, Dell, Solution, Atmosphere, Woman, AMD, Interest, D&H, HPE, VAR, UCC, D&H Distributing, SMB, CRN, History, Technology, Industry, Intel, Twitter, Prize for Liberty, Week, Female, Channel, Microsoft, Pandemic, HP, Television, Sport, Digital imaging, Electronics, MSP, Organization, Education, Cisco Systems, Google Cloud, Growth, GLOBE, D, ESOP, Marketing, Esports, The Channel Company, Cloud computing, Facebook, Fundación ProAves, Management, Cassette tape

This years Top Influencers list includes C-level leaders from AMD, Cisco, Dell, HP, HPE, Intel, Lenovo, Microsoft, Google Cloud, and others.

Key Points: 
  • This years Top Influencers list includes C-level leaders from AMD, Cisco, Dell, HP, HPE, Intel, Lenovo, Microsoft, Google Cloud, and others.
  • The series is part of The Channel Companys Women of the Channel Leadership Network, an online community dedicated to helping women across the IT channel thrive both professionally and personally.
  • Jenn has previously also been named to the CRN Women of the Channel and the Power 100 Women of the Channel lists, and has been named among the CRN Channel Chiefs multiple years running.
  • CRN also recognized Maria this year in its Women of the Channel feature, making her first appearance on this prestigious list of visionary leaders.

Gaming And Technology Pioneer Frank Azor Joins The Board Of Eyesafe

Retrieved on: 
Thursday, August 26, 2021
Industry, General manager, AMD, Friends, Human, Azor, Adoption, Dell, Solution, G series, XPS, Health, Privately held company, Business development, Electronics, Learning, Multimedia, Color, Dell Technologies, Inc. (magazine), IP, Technology, Video game, Toy

Frank Azor joins the Eyesafe Board of Directors to accelerate its penetration into the fast-growing PC gaming industry.

Key Points: 
  • Frank Azor joins the Eyesafe Board of Directors to accelerate its penetration into the fast-growing PC gaming industry.
  • "Frank brings decades of experience and expertise to the Eyesafe board," said Justin Barrett, co-founder and Chief Executive Officer of Eyesafe.
  • "His deep knowledge of the gaming industry will power our expansion plans across displays targeting the consumer and gaming markets."
  • "Frank is a globally recognized pioneer in the gaming business and his addition to the Eyesafe board will accelerate adoption of our standards and IP solutions across this important market."

iBUYPOWER Announces Weeklong Stream Schedule for Intel Gamer Days

Retrieved on: 
Wednesday, August 25, 2021
AMD, MLG, 53rd Anniversary of Lucha Libre in Estado de México, Minecraft, Intel, LAN, Cartoon, Sonic the Hedgehog 2 (film), Strength, Microsoft, Memory Lane, PC, ASUS, WD, Music, Sonic Mania, Partnership, YouTube, Cartoon Network, Chimera, Computer, Wonders, RDY, Technology, Personal computer, Video game, Auction

LOS ANGELES, Aug. 25, 2021 /PRNewswire-PRWeb/ --iBUYPOWER, a leading manufacturer of high-performance custom gaming PCs, today announced its weeklong stream schedule, in celebration of Intel Gamer Days, with two PC giveaways, special guests, product launches, and new deals announced every day.

Key Points: 
  • LOS ANGELES, Aug. 25, 2021 /PRNewswire-PRWeb/ --iBUYPOWER, a leading manufacturer of high-performance custom gaming PCs, today announced its weeklong stream schedule, in celebration of Intel Gamer Days, with two PC giveaways, special guests, product launches, and new deals announced every day.
  • iBUYPOWER will kick off its stream on August 30th within iBPCRAFT , its custom designed Minecraft server, created in partnership with Intel, and conclude on September 3rd.
  • At the end of the stream iBUYPOWER will announce the final opportunity to win an iBUYPOWER gaming PC.
  • iBUYPOWER has worked intimately with brands such as Intel, NVIDIA, AMD, Microsoft, WD, ASUS, Bethesda, MLG and many more.

ASUS Introduces the Build Together, Give Together Charity Challenge

Retrieved on: 
Wednesday, August 25, 2021
Electronic Design Automation, Philanthropy, Consumer Electronics, Technology, Other Philanthropy, Fund Raising, Hardware, Storm, Open Platform, Industry, Micro Center, Align Technology, AMD, Friends, Intel, Twitter, Instagram, NVIDIA, Organic, PC, D, Best Buy, Multimedia, D&H Distributing, North America, Solution, YouTube, LinkedIn, Gamers Outreach Foundation, Digital Storm, Future US, Technology, Company, Incredible, Personal computer, Toy, Video game, Industrial gas

ASUS today announced the Build Together, Give Together charity challenge, inviting PC builders, gamers and modders to build for a cause starting on August 24th.

Key Points: 
  • ASUS today announced the Build Together, Give Together charity challenge, inviting PC builders, gamers and modders to build for a cause starting on August 24th.
  • In celebration of the growing PC building community, the Build Together, Give Together challenge encourages aspiring builders and tech enthusiasts alike to share their PC build and donate to their favorite charity.
  • To learn more about and participate in the Build Together, Give Together charity challenge, visit our website here: https://www.asus.com/microsite/build-together-give-together/ .
  • View the full release here: https://www.businesswire.com/news/home/20210825005194/en/
    Join in with ASUS and industry partners for the Build Together, Give Together challenge benefitting the charity of your choice!

Flex Logix Appoints Lee Leibig As Vice President Of Sales For AI Inference

Retrieved on: 
Wednesday, August 25, 2021
IRI, AMD, Growth, Software, Motivation, Silicon, Cypress, Semiconductor, AI, Senior, Solution, Marketing, Algorithm, EMEA

MOUNTAIN VIEW, Calif., Aug. 25, 2021 /PRNewswire/ -- Flex Logix Technologies, Inc ., supplier of the fastest and most-efficient AI edge inference accelerator and the leading supplier of eFPGA IP,today announced the appointment of Lee Leibig as Vice President of North America and Europe, Middle East, and Africa (EMEA) Sales for AI inference products.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 25, 2021 /PRNewswire/ -- Flex Logix Technologies, Inc ., supplier of the fastest and most-efficient AI edge inference accelerator and the leading supplier of eFPGA IP,today announced the appointment of Lee Leibig as Vice President of North America and Europe, Middle East, and Africa (EMEA) Sales for AI inference products.
  • Lee brings a wealth of experience to Flex Logix having been Vice President of Sales for Broadband Semiconductors in Broadcom's global sales team.
  • "The customer activity for our AI inferencing products is growing rapidly due to their ability to outperform competitive solutions on price and performance," said Dana McCarty, Vice President of Sales and Marketing for Flex Logix's Inference Products.
  • "Lee has extensive experience leading sales teams to capitalize on high-growth opportunities and will be instrumental in helping Flex Logix secure a leadership role in this space."